Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Summary

The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.

Timeline

Start

2018-03-05

Primary completion

2019-03-15

Completion

2019-03-15

Outcome

Outcome not reported

Stopped (Enrollment): “Cancel Enrollment due to Covid-19 Pandemic, Not restarted”

Drugs

Indications